我們已在上線！進一步了解

Enovis

ENOV

市值 US$11.3億

19.59 USD

+0.24

1.24%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

19.62

+0.03

0.15%

1天

1.24%

5天

12.14%

1個月

4.98%

3個月

-30.21%

6個月

-22.26%

今年迄今

-26.1%

1年

-37.19%

5年

-77.34%

10年

-61.1%

關於： Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

員工： 7,802

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 33.3%

中性 61.1%

負面 5.6%

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th

Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning.

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis ™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

The Motley Fool

Insider at Medical Device Maker Buys More Than 7,500 Shares

The acquisition involved 7,598 shares at a weighted average price of $19.74 per share, representing a total investment of ~$150,000. The transaction size equals 14% of the equity stake held by the executive before the filing.

Insider at Medical Device Maker Buys More Than 7,500 Shares

Zacks Investment Research

What Makes Enovis (ENOV) a New Buy Stock

Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Enovis (ENOV) a New Buy Stock

Zacks Investment Research

Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition

ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.

Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition

Enovis Corporation (ENOV) M&A Call Transcript

Enovis Corporation (ENOV) M&A Call Transcript

Enovis Corporation (ENOV) M&A Call Transcript

Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal

Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery.

Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal

eCential Robotics Announces Binding Offer from Enovis

eCential Robotics platform to join Enovis' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn.

eCential Robotics Announces Binding Offer from Enovis

Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics

Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more comprehensive ecosystem designed to improve surgical precision, streamline workflows, and enhance patient outcomes.

Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics

查看新聞排名

價格圖表採用Lightweight Charts™實作